Pseudocowpox (PCPV): A next generation viral vector for cancer immunotherapy

**OBJECTIVE**

New tools for therapeutic vaccination

**MATERIALS AND METHODS**

We screened a variety of viruses to identify vectors more likely to induce the immune response. To this end, we exposed human PBMCs to these viruses and measured their capacity to trigger the release of IFN-alpha as a surrogate marker of their immunogenic properties. In parallel, we measured the ability of these viruses to induce antigen-specific immunity in a mouse colonic tumor model.

**RESULTS**

PCPV showed remarkable ability to induce IFN-alpha in human PBMCs.

**CONCLUSIONS**

PCPV can be used as a next generation viral vector for cancer immunotherapy.